An apparatus for glycan analysis is disclosed. The apparatus includes a plurality of loading wells adapted to receive a plurality of samples; a plurality of capillaries arranged in correspondence with the loading wells, each of the capillaries including a first portion including a stacking gel and a second portion including a resolving gel; and a plurality of eluting wells arranged in correspondence with the capillaries and adapted to receive a portion of the samples having traversed the capillaries.

The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method using magnetic beads containing negatively charged carboxyl groups extending from the surface of the magnetic beads.

Disclosed herein are glyco-decoy acceptor compositions that sidetrack or inhibit the activity of biosynthetic enzymes participating in synthesis of ligands binding at selectin, galectin and siglecs receptors; methods of their preparation and uses in drug discovery and in treatments of diseases.

A sample, which is a mixture of glycans, is fluorescently labeled (S2). The sample is subsequently separated by microchip electrophoresis under a buffer solution with no lectin added as well as under multiple kinds of buffer solutions with different lectins respectively added, and the separated components are fluorescently detected (S3). A high-concentration gel which can produce a molecular-sieving effect is used as the buffer solution. Multiple electropherograms are created from the detection results (S4). A glycan having a lectin specifically attached is delayed during its migration in the buffer solution, so that a peak corresponding to this glycan will effectively disappear. Accordingly, based on the kinds of lectins and the presence/absence of a peak on each of the electropherograms, the structure of each glycan in the sample is estimated and the glycan is identified (S5).

A method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfatide included in cerebrospinal fluid, the method including adding an internal standard substance to a solution including the cerebrospinal fluid, submitting the solution including the cerebrospinal fluid, to which the internal standard substance has been added, to liquid chromatography to obtain an eluate, and subjecting the eluate to mass analysis.

The invention provides cereal plants having a high level of fructan useful for the production of a range of food, beverage, nutraceutical and pharmaceutical products. The invention provide, methods of producing high-fructan products from plants modified to comprise a reduced level of an endogenous polypeptide with starch synthase activity, and products so produced. In some embodiments, plants are modified by introduction of an agent such as a nucleic acid molecule which down regulates endogenous starch synthase II gene expression.

The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method using magnetic beads containing negatively charged carboxyl groups extending from the surface of the magnetic beads.

Disclosed are an antibody or a functional fragment thereof binding to 3′-sialyl lactose and comprising a heavy chain variable region which is optionally substituted with 3 or less amino acids and which comprises a CDR sequence consisting of an amino acid sequence ARKNGGLDYAMDY (SEQ ID NO: 3), a polynucleotide encoding the antibody or the functional fragment thereof, an expression vector comprising the polynucleotide, and a test drug for a disease and a pharmaceutical composition comprising the antibody or the functional fragment thereof.

This disclosure provides a novel method of controlling the glycosylation profile of a protein during production. The disclosure also provides a novel method of improving protein yield while controlling the glycosylation profile of a protein.

Coliform detection is provided via the alpha (“α”) form of enzyme substrates. The α form can be mixed with a dry growth media suitable for target Coliforms and then applied as needed to a test card format, or then mixed with water and sterilized for use a broth applied to a membrane filter detection device, for example.